Key result
Nesiritide (Natrecor), a recombinant human B-type natriuretic peptide, is reviewed for its indications, dosing, and clinical trial evidence in acutely decompensated congestive heart failure.
Nesiritide is a recombinant human B-type natriuretic peptide approved for the treatment of acutely decompensated congestive heart failure.
Answers are grounded in this paper and cite their sources.
Nesiritide may warrant consideration in ADHF per reviewed evidence; leaves open optimal use pending further RCTs.
The care of the patient experiencing acutely decompensated congestive heart failure requires therapies that promote vasodilation and increase cardiac output while decreasing symptomatic hypotension and dysrhythmias. Nesiritide (Natrecor) is a new type of drug, recombinant human B-type natriuretic peptide (hBNP), approved for use in acutely decompensated congestive heart failure. The neurohormonal effects of endogenous BNP are reproduced by nesiritide. Indications, dosing, administration, and review of clinical trials are presented in this article.
No takes yet. Share an insight, caveat, or question.
Colbert et al. (2003) conducted a review in Acutely decompensated congestive heart failure. Nesiritide (Natrecor) was evaluated. Nesiritide (Natrecor), a recombinant human B-type natriuretic peptide, is reviewed for its indications, dosing, and clinical trial evidence in acutely decompensated congestive heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: